Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer

Zhipeng Chen1, Zhenzhen Fan1, Xiaowei Dou2

  • 1Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.

Theranostics
|October 14, 2020
PubMed

Insights

Clusterin (CLU) acts as a tumor suppressor in lung cancer. Loss of CLU creates vulnerabilities that can be targeted with TAK1 inhibitors for precision medicine in non-small cell lung cancer (NSCLC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Precision Medicine

Background:

  • Drug resistance limits precision medicine efficacy in cancer treatment.
  • Tumor suppressor genes (TSGs) are crucial in tumorigenesis and influence treatment outcomes.
  • Clusterin (CLU) function in lung cancer requires further elucidation.

Purpose of the Study:

  • To investigate the tumor suppressive role of Clusterin (CLU) in lung cancer.
  • To delineate the signaling pathways affected by CLU loss-of-function in non-small cell lung cancer (NSCLC).
  • To explore precision medicine strategies for CLU-deficient lung cancers.

Main Methods:

  • Analysis of clinical, in vitro cell line, and in vivo mouse model data.
  • Delineation of the signaling cascade involving CLU, TGFBR1, TRAF6/TAB2/TAK1, and NF-κB.
  • Testing of TAK1 inhibitors and combination therapies in CLU-deficient NSCLC models.

Main Results:

  • CLU functions as a potent tumor suppressor gene in lung cancer.
  • CLU loss activates TAK1-NF-κB signaling by inhibiting TGFBR1 recruitment of the TRAF6/TAB2/TAK1 complex.
  • CLU-deficient lung cancer cells exhibit sensitivity to TAK1 inhibitors, particularly in Kras-mutated NSCLC.

Conclusions:

  • Combinational therapy with TAK1 and MEK1/2 inhibitors effectively reduces tumor size in Kras-mutated, CLU-deficient NSCLC.
  • Loss of TSG function can reprogram cellular signaling networks, creating therapeutic vulnerabilities.
  • Targeting these reprogrammed pathways offers a novel precision medicine approach for resistant lung cancers.

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K